| Characteristics | STABLE‐SR, n = 102 | CPVI alone, n = 102 | p‐Value |
|---|---|---|---|
| Age, years | 70.0 (67.4–74.01) | 69.3 (66.8–73.3) | 0.308 |
| AF duration, months | 24 (6.0–60.3) | 24 (6.8–37.3) | 0.257 |
| BMI, kg/m2 | 24.2 ± 3.4 | 24.6 ± 3.0 | 0.361 |
| <25, n (%) | 38 (39.2) | 40 (39.6) | |
| ≥25, n (%) | 59 (60.8) | 61 (60.4) | |
| Comorbidities, n (%) | |||
| Hypertension | 58 (56.9) | 69 (67.7) | 0.112 |
| Diabetes | 14 (13.7) | 18 (17.7) | 0.441 |
| CAD | 22 (21.6) | 25 (24.5) | 0.618 |
| Stroke or TIA | 5 (4.9) | 6 (5.9) | 0.757 |
| Congestive heart failure | 0 (0.0) | 1 (1.0) | 1.000 |
| COPD | 0 (0.0) | 1 (1.0) | 1.000 |
| OSAS | 0 (0.0) | 0 (0.0) | / |
| NYHA functional class | 0.445 | ||
| I | 96 (98.0) | 93 (94.9) | |
| II | 2 (2.0) | 5 (5.1) | |
| III | 0 (0.0) | 0 (0.0) | |
| CHA2DS2‐VA score, n (%) | 0.169 | ||
| 1 | 31 (30.4) | 18 (17.7) | |
| 2 | 35 (34.3) | 45 (44.1) | |
| 3 | 24 (23.5) | 24 (23.5) | |
| >3 | 12 (11.8) | 15 (14.7) | |
| LAD, mm | 39 (35–42) | 38 (35–42) | 0.978 |
| LVEF, % | 62.75 ± 4.58 | 62.37 ± 5.27 | 0.587 |
| Medication use, n (%) | |||
| Class I AAD | 17 (16.7) | 21 (20.6) | 0.472 |
| Class III AAD | 27 (26.5) | 27 (26.5) | 1.000 |
| ACEI or ARB | 24 (23.5) | 32 (31.4) | 0.209 |
| Beta blocker | 33 (32.4) | 32 (31.4) | 0.881 |
| CCB | 19 (18.6) | 19 (18.6) | 1.000 |
| Digoxin | 0 (0.0) | 1 (1.0) | 1.000 |
AAD, denotes antiarrhythmic drugs; ACEI, angiotensin‐converting enzyme inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CCB calcium channel blocker; COPD, chronic obstructive pulmonary disease; CPVI, circumferential pulmonary vein isolation; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association heart failure classification; OSAS, obstructive sleep apnoea syndrome; TIA, transient ischaemic attack.
a
Plus‐minus values are means ±SD.